- P-ISSN 2233-4203
- E-ISSN 2093-8950
DC23, a triazolothione resorcinol analogue, is known to inhibit heat shock protein 90 and pyruvate dehydrogenase kinase which are up-regulated in cancer and diabetes, respectively. This study was performed to elucidate the metabolism of DC23 in human liver microsomes (HLMs). HLMs incubated with DC23 in the presence of uridine 5’-diphosphoglucuronic acid (UDPGA) and/or β-nicotinamide adenine dinucleotide phosphate (NADPH) resulted in the formation of four metabolites, M1- M4. M1 was identified as DC23-N-Oxide, on the basis of LC-MS/MS analysis. DC23 was further metabolized to its glucuronide conjugates (M2, M3, and M4). In vitro metabolic stability studies conducted with DC23 in HLMs revealed significant glucuron- ide conjugation with a t 1/2 value of 1.3 min. The inhibitory potency of DC23 on five human cytochrome P450s was also investi- gated in HLMs. In these experiments, DC23 inhibited CYP2C9-mediated tolbutamide hydroxylase activity with an IC 50 value of 8.7 µM, which could have implications for drug interactions.
Sidera, K.. (2014). . Recent Pat Anticancer Drug Discov, 9, 1-.
Jeong, J. H.. (2016). . Eur. J. Med. Chem., 124, 1069-. http://dx.doi.org/10.1016/j.ejmech.2016.10.038.
Fuhrmann-Stroissnigg, H.. (2017). . Nat. Commun., 8, 422-. http://dx.doi.org/10.1038/s41467-017-00314-z.
정주희. (2017). Chalcone-templated Hsp90 inhibitors and their effects on gefitinib resistance in non-small cell lung cancer (NSCLC). Archives of Pharmacal Research, 40(1), 96-105.
Sharp, S. Y.. (2007). . Mol. Cancer Ther., 6, 1198-. http://dx.doi.org/10.1158/1535-7163.MCT-07-0149.
Feldman, R. I.. (2009). . Chem. Biol. Drug Des., 74, 43-. http://dx.doi.org/10.1111/j.1747-0285.2009.00833.x.